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Use of recombinant human parvovirus B 1 9 antigens in serological assays H A Cubie, E E Leslie, S Smith, H J O'Neill, H Hart, B J Cohen, J M Inglis Abstract Aims-To compare the sensitivity, specificity, and practicality of recombinant proteins in serological tests for the detection of human parvovirus B19 IgG and IgM. Methods-Indirect enzyme linked immunosorbent assays using B19 structural proteins expressed in Escherichia coli were developed for the detection of B19 specific IgG and IgM (rELISA-G and rELISA-M). Cells infected with baculovirus expressing B19 structural proteins were also used in an indirect immunofluorescence assay for IgG and IgM antibodies (IFA-G and IFA-M). Antibody capture radioimmunoassays for IgG and IgM (GACRIA and MACRIA) were used as comparative assays. Results-Twenty nine pools of intravenous immunoglobulin were clearly positive for B19 IgG by rELISA-G and contained low IgG titres by GACRIA. From 113 samples tested by all methods, sensitivities of 92% (77184) and 97% (68/70) were obtained for ELISA and immunofluorescence, respectively, when compared with GACRIA. One hundred and sixteen samples from patients presenting with rash or arthralgia were compared by MACRIA, rELISA-M, and IFA-M. Sensitivities of both recombinant tests were more than 95%. Despite pretreatment to remove IgG or rheumatoid factor, false positive results were a problem in the rELISA-M but were not seen with the IFA-M. Conclusions-The limited supply of native antigen has severely restricted the wide application of serology for parvovirus B19. The use of recombinant antigens permitted the introduction of local screening tests which had many advantages, including quicker results and relief of the burden on the Reference Laboratory. The use of rELISA-M for sensitivity and IFA-M for specificity and confirmation proved a useful and practical combination for diagnosis of recent infection with B19, and rELISA-G allowed the immune response to be determined in selected populations.
(i Clin Pathol 1993;46:840-845) Human parvovirus B19 is the causative agent of the common childhood infection, erythema infectiosum. B 19 is also a major cause of aplastic crises'; there is also a 9% risk of fetal loss in infected pregnancy2; it can cause hydrops fetalis, especially with mid-trimester infection3; and recently, it has been shown to be the cause of persistent severe anaemia in immunocompromised individuals, including children with acute lymphatic leukaemia (ALL) and patients with HIV infection. 45 Until recently the most useful serological tests for the detection of IgM antibodies to B19 were the anti-,u capture radioimmunoassay (MACRIA)6 or enzyme linked immunosorbent assay (ELISA).7-9 These tests, however, were established with antigen derived from the plasma or serum of viraemic patients and this has restricted their availability to a few centres. The lack of native antigen has also severely restricted the development of B 19 IgG assays as screening tests for evidence of past infection. More recently, expression systems, both prokaryotic and eukaryotic, have been described'>'4 and used for serological investigations. These test systems, based on immunofluorescence, ,i-capture, and indirect ELISA showed good correlation with MACRIA results. An evaluation of a commercially available ELISA using a B 19 specific synthetic peptide, however, suggested lower sensitivity and specificity than MACRIA.'5 Clearly more extensive comparisons and evaluations are required before alternatives to tests using native antigen are introduced more widely.
A baseline screen for newly diagnosed patients with leukaemia, chronic haemolytic anaemia, haemophilia, HIV infection, and for potential bone marrow transplant patients would be useful. Pregnant women exposed to B19 infection and laboratory staff working with specimens containing parvovirus should also be screened.2 Screening was carried out in a recently described outbreak of B 19 infection in a paediatric ward and people at risk were excluded.'6 Our aim was to produce tests for specific IgM and IgG with similar laboratory protocols such that they could be done at the same time, using minimum sample volume, and as economically as possible.
Methods
The following were tested for B19 IgG by ELISA: a panel of 13 For indirect immunofluorescence assay, insect cells infected with baculovirus recombinant expressing the VP1 protein of B19 were spotted on to glass slides. Slides were either fixed in methanol or by heat and acetone. The IFA was carried out essentially as described by Brown et al2 with the following minor modifications: blocking was carried out using veronal-buffered saline containing 1% guinea pig complement, and the same diluent was used to dilute sera; "GullSORB" was used as described above for the rELISA-M test; sheep anti-human IgG and IgM sera conjugated to fluorescein isothiocyanate (FITC) were provided by the Scottish Antibody Production Unit (Carluke) and slides were mounted in a 50% glycerol-phosphate buffer, pH8-4. IgG (IFA-G) and IgM (IFA-M) tests were routinely carried out at a serum dilution of 1 in 16.
Antibody capture radioimmunoassays for B19 IgM (MACRIA) and IgG (GACRIA) were done as previously described. 6 The results of RIA were expressed in arbitrary units (AU).
The presence of rheumatoid factor in a specimen was detected by latex agglutination (Wellcome Diagnostics). Interference from rheumatoid factor was reduced by pretreating the specimen with anti-human IgG and the absence of IgG in the treated sample was checked by ELISA. In some specimens it was removed by double absorption with heataggregated y-globulin for 1 hour at 37°C and then overnight at 4°C. Twenty nine samples of stored intravenous immunoglobulin plasma pools were tested in the rELISA-G. All samples gave a clearly positive T:CO (>2 0 for all samples on replicate testing). Dilution in PBST + 1% BSA, however, suggested that the titre of most samples was fairly low, with 21 giving negative ratios at a dilution of more than 1 in 800. Low antibody titres were also Absorbances ofcontrol panel ofsera (13 samples from Germany, labelled GP1-GP13) obtained by rELISA-G on different occasions. GP1 GP3 GP5 GP7 GP9 GP11 GP13 GP2 GP4 GP6 GP8 GP1o GP12 The standard pretest procedure was to remove IgG using "GullSORB", and this was used for all IgM tests described above. Several combinations of pretreatment were investigated in an attempt to reduce the number of false positive rELISA-M results:
(a) Pretreatment with heat-aggregated yglobulin The supematant fluid, following the double absorption procedure, was diluted 1 in 80 in PBST + 1%BSA and the ELISA carried out as before. All sera gave the same Table 4 (b) Combined absorption to remove IgG (standard "GuIISORB" treatment) followed by removal of rheumatoid factor overnight at 4°C with heat-aggregated y-globulin) Of 12 sera containing B 19 specific IgM, one became negative and one equivocal after such treatment; of 25 problematic sera, 17 remained false positive, one gave a borderline positive result, and seven had become negative.
Neither (a) nor (b) significantly improved the specificity and the standard pretreatment procedure has therefore been retained for future testing.
Discussion
The B 19 ELISAs were easy to perform and gave reproducible results both within assays and from day to day. The antigens supplied by Mikrogen were stable at 4°C and have now been in use for up to 18 months without deterioration. Minimum sample volume was required (3 u1 of serum for rELISA-G and 5 ,ul for rELISA-M). Reagent costs have been estimated to be less than 70p for duplicate testing and the rELISA-G could therefore offer a simple, inexpensive screening test which in our sample gave good agreement with GACRIA and IFA-G. The recent development of commercially available assays using recombinant proteins should allow much more extensive comparisons in the future. In the current study 70% of sera studied gave positive results by rELISA-G, a finding comparable with the 60% of blood donors shown to be positive by GACRIA6 and the 76% of blood donors positive by IFA-G. and this has been noted by other workers, particularly when rheumatoid factor negative, rubella IgM containing sera were examined.921 The use of antibody capture assays can reduce the problem of false positive results considerably. Recent experience in our own laboratory with commercially available indirect and ,u-capture ELISA tests for rubella, however, have shown a loss of sensitivity at the expense of specificity (unpublished observations) .
In another study Brown and colleagues found cross-reactivity in 24 sera containing rubella specific IgM which was apparently not evident when indirect immunofluorescence was used. ' The continued provision of a regular and adequate supply of quality assured slides for IFA is currently being undertaken. Together with the purchase of tested recombinant B 19 antigen for ELISA, this would enable B19 serology to be undertaken locally. Such testing would relieve the burden on the Reference Laboratory, which could still provide reference assays with native B 19 antigens when required. Local testing would also ensure a quicker and cheaper service to the clinicians and would enable outbreaks to be recognised earlier because of the closer contact between the reporting laboratory and the clinicians. With the advent of purchaser/ provider services such local arrangements will be valuable in the future.
In conclusion, we suggest that the B 19 ELISA described here, using recombinant proteins to detect both IgG and IgM and giving results within one day, would be suitable for use at a local level and that the provision of IFA slides with insect cells expressing B19 proteins would provide a confirmatory assay suitable for smaller numbers of samples. 
